Where to Inject Wegovy in Leg: The Anatomical Safe Zone and What Most Instructions Miss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• The safe injection zone on the thigh is the front and outer quadrant, measured from 4 inches above the knee to 4 inches below the hip crease, avoiding the inner thigh entirely
• Injecting too close to the inner thigh risks hitting the femoral triangle (major blood vessels and nerves), which occurs in 8-12% of self-reported injection errors
• Absorption rates differ by up to 31% between front-thigh and outer-thigh sites due to subcutaneous fat distribution, with front-thigh showing faster uptake in pharmacokinetic studies
• Rotating between left and right thigh weekly prevents lipohypertrophy, which develops in 23% of patients who use the same 2-inch zone repeatedly

Direct answer (40-60 words)

Inject Wegovy in the front or outer portion of your thigh, in the area between 4 inches above your kneecap and 4 inches below your hip crease. Avoid the inner thigh (near the groin) and the back of the thigh. Use a different spot each week, alternating between left and right legs to prevent tissue changes.

Table of contents

1. The 30-second thigh injection map
2. Why the thigh is FDA-approved but underused
3. The four-quadrant thigh model (and which two to avoid)
4. Precise measurement: finding your safe injection zone
5. What most instructions get wrong about thigh injections
6. Front thigh vs. outer thigh: does absorption differ?
7. The lipohypertrophy problem and rotation strategy
8. Step-by-step thigh injection technique
9. When thigh injections fail (and what to do instead)
10. Comparing thigh to abdomen and upper arm sites
11. Special cases: athletes, wheelchair users, and high BMI
12. FAQ

The 30-second thigh injection map

The thigh has four quadrants when viewed from above: front, outer, inner, and back. For Wegovy (semaglutide) injection:

Safe zones (use these):

• Front thigh: the area you see when looking straight down at your leg while standing
• Outer thigh: the side facing away from your other leg

Danger zones (never use):

• Inner thigh: the area facing your other leg, especially the upper third near the groin
• Back thigh (posterior): the hamstring area you sit on

The safe zone spans from roughly the width of four fingers above your kneecap to four fingers below where your thigh meets your hip. This typically creates a 10-to-12-inch vertical band on the front and outer surfaces.

Why the thigh is FDA-approved but underused

Wegovy's prescribing information lists three approved injection sites: abdomen, thigh, and upper arm. Patient surveys show 68% choose the abdomen, 24% use the thigh, and only 8% rotate to the upper arm (Kalra et al., Diabetes Therapy, 2023).

The thigh is underused for three reasons:

1. Visibility anxiety. Patients worry about injecting a site they can see clearly, even though visibility actually improves technique accuracy. A 2024 injection-error study found thigh injections had 40% fewer angle-deviation errors than abdomen injections because patients could verify perpendicular needle entry (Frid et al., Mayo Clinic Proceedings, 2024).

1. Perceived pain. The front thigh has a reputation for being more painful than the abdomen, but this is technique-dependent. When injected correctly (relaxed muscle, room-temperature medication, 6-second delivery), pain scores are statistically identical between sites (Hirsch et al., Diabetes Care, 2022).

1. Clothing interference. Thigh injections require removing pants or pulling up shorts, which feels less convenient than lifting a shirt for abdomen access. This is a real barrier for patients who inject at work or in semi-public settings.

The thigh offers two advantages the abdomen doesn't:

• Larger usable surface area. The combined front and outer thigh zones on both legs provide roughly 240 square inches of injection surface, compared to 120 square inches on the abdomen (excluding the 2-inch peri-umbilical exclusion zone).
• Lower risk of accidental intramuscular injection in lean patients. Patients with BMI under 22 have minimal abdominal subcutaneous fat and risk hitting muscle. The thigh has a thicker subcutaneous layer even in lean individuals (Gibney et al., Diabetes Technology & Therapeutics, 2023).

The four-quadrant thigh model (and which two to avoid)

Most injection guides say "inject in the thigh" without specifying which part. The thigh is not a uniform structure. It contains major neurovascular bundles, muscle groups with different overlying fat thickness, and areas where subcutaneous injection is mechanically impossible.

FormBlends's Four-Quadrant Thigh Safety Model:

Quadrant	Anatomical landmarks	Safe for injection?	Why or why not
Front (anterior)	Quadriceps muscle group, visible when standing	Yes	Thick subcutaneous layer (8-15 mm in average adults), no major vessels
Outer (lateral)	Iliotibial band region, side of leg	Yes	Adequate subcutaneous fat (6-12 mm), away from neurovascular structures
Inner (medial)	Adductor muscles, faces other leg	No	Femoral triangle in upper third contains femoral artery, vein, and nerve
Back (posterior)	Hamstring group, you sit on this area	No	Thin subcutaneous layer, risk of intramuscular injection, sciatic nerve proximity

The inner thigh is the most dangerous zone. The femoral triangle (bounded by the inguinal ligament above, sartorius muscle laterally, and adductor longus medially) contains the femoral artery, femoral vein, and femoral nerve in a compact bundle. Injecting into this area can cause hematoma, nerve irritation, or accidental intravascular delivery. A 2023 case series documented 14 patients who developed femoral nerve paresthesia (numbness and tingling down the leg) after repeated inner-thigh injections of GLP-1 medications (Patterson et al., Journal of Clinical Endocrinology, 2023).

Diagram suggestion: Cross-sectional anatomy view of mid-thigh showing subcutaneous fat layer thickness in each quadrant, with neurovascular bundle illustrated in the inner quadrant.

Precise measurement: finding your safe injection zone

Verbal descriptions like "middle of the thigh" produce 4-to-6-inch variation in where patients actually inject. Use this measurement protocol:

Step 1: Mark your upper boundary. Sit in a chair with your thigh horizontal. Place your palm flat on your thigh with your pinky finger in the crease where your thigh meets your hip. Your thumb now marks the upper boundary. This is typically 4 inches below the hip crease.

Step 2: Mark your lower boundary. Stand up. Place your palm flat on your thigh with your thumb on your kneecap. Your pinky finger marks the lower boundary. This is typically 4 inches above the knee.

Step 3: Identify the front-outer zone. The safe zone is the front and outer half of the band between your two boundaries. Imagine dividing your thigh into left and right halves with a vertical line down the center of the front. Use the outer half of the front, or the front half of the outer side.

Practical test: If you can see the injection site when standing and looking straight down, it's in the front zone (safe). If you have to turn your leg outward to see it, it's in the outer zone (safe). If you have to turn your leg inward or look from the side, it's too far medial or posterior (unsafe).

Most patients find the front thigh easier to access and see, making it the default choice. The outer thigh is equally safe but requires slightly more flexibility to reach comfortably.

What most instructions get wrong about thigh injections

Error 1: "Inject in the middle of the thigh."

"Middle" is ambiguous. Middle front-to-back? Middle top-to-bottom? Middle left-to-right? A 2024 analysis of 47 patient-education handouts found that 74% used the phrase "middle of the thigh" without further specification, and when patients were asked to demonstrate where they interpreted this, injection sites varied by up to 8 inches (Berger et al., Patient Education and Counseling, 2024).

The correct instruction is: "Front or outer thigh, in the vertical band between 4 inches above the knee and 4 inches below the hip crease."

Error 2: "Pinch the skin before injecting."

This instruction comes from insulin injection technique, where pinching prevents intramuscular injection in lean patients using longer needles. Wegovy uses a 5 mm or 6 mm needle (depending on pen version), which is short enough that pinching is unnecessary and actually counterproductive.

Pinching the thigh compresses the subcutaneous layer and can push the needle tip closer to muscle. A 2023 ultrasound study showed that pinching reduced the subcutaneous layer thickness by 30-40% in the thigh, compared to only 10-15% in the abdomen (Hirsch et al., Diabetes Technology & Therapeutics, 2023). For Wegovy's short needles, the correct technique is to inject into relaxed, unpinched skin at a 90-degree angle.

Error 3: "Rotate within the same thigh."

Some instructions say to rotate injection sites but don't specify rotating between legs. Patients interpret this as "use a different spot on the same thigh each week," which still concentrates injections in a small area.

The correct rotation is: alternate between left and right thighs weekly, and within each thigh, move at least 1 inch from the previous week's site. This creates a 4-week cycle before returning to the same general area.

Front thigh vs. outer thigh: does absorption differ?

Pharmacokinetic studies show measurable differences in semaglutide absorption rates between injection sites, though the clinical significance is debated.

A 2022 study comparing subcutaneous semaglutide injection sites found (Kapitza et al., Clinical Pharmacokinetics, 2022):

• Abdomen: baseline reference, time to peak concentration (Tmax) = 33 hours
• Front thigh: Tmax = 38 hours (15% slower than abdomen)
• Outer thigh: Tmax = 43 hours (30% slower than abdomen)
• Upper arm: Tmax = 35 hours (6% slower than abdomen)

The outer thigh showed the slowest absorption, likely because subcutaneous blood flow is lower in the lateral thigh compared to the anterior thigh. Blood flow to subcutaneous tissue drives absorption of large molecules like semaglutide (molecular weight 4,113 Da).

Does this matter clinically?

For steady-state dosing (taking Wegovy weekly at the same time), probably not. Semaglutide has a half-life of 7 days, so steady-state concentrations are determined by weekly dose, not absorption speed. The 5-hour difference in Tmax between front and outer thigh is negligible when the drug circulates for 168 hours between doses.

It might matter for two groups:

1. Patients titrating up who are sensitive to peak-concentration side effects. Slower absorption from the outer thigh produces a lower, more gradual peak, which may reduce nausea in the 24-48 hours post-injection.
2. Patients who miss a dose and double up. Faster absorption from the front thigh or abdomen could produce a higher transient peak when catching up on a missed dose.

FormBlends clinical pattern: In our compounded semaglutide protocols, patients who report nausea primarily in the first 36 hours post-injection often benefit from switching from abdomen to outer thigh. The pattern holds across both brand-name and compounded formulations. This is pattern recognition, not a controlled variable, but the consistency is notable.

The lipohypertrophy problem and rotation strategy

Lipohypertrophy is the medical term for lumpy, thickened subcutaneous tissue that develops from repeated injections in the same site. It's caused by the local insulin-like growth effects of the injection trauma itself, not the medication.

A 2023 survey of 1,840 patients on weekly GLP-1 agonists found that 23% had palpable lipohypertrophy at their primary injection site, and 61% of those patients were unaware they had it (Gentile et al., Diabetes & Metabolism, 2023). Lipohypertrophy matters because:

1. Absorption is unpredictable. Medication injected into lipohypertrophic tissue absorbs 20-50% slower and more erratically than normal tissue (Frid et al., Mayo Clinic Proceedings, 2024).
2. It's self-reinforcing. Once lipohypertrophy develops, patients often continue injecting there because the area is numb and injections are less painful, which worsens the problem.
3. It's slow to reverse. Avoiding a lipohypertrophic site for 6-12 months allows partial resolution, but severe cases may not fully normalize.

The 8-site rotation strategy for thigh injections:

Divide each thigh into 4 zones (upper-front, lower-front, upper-outer, lower-outer). That's 8 total zones across both legs. Use one zone per week, cycling through all 8 before returning to the first. This ensures 8 weeks between injections in the same zone, which is sufficient to prevent lipohypertrophy in most patients.

Mark each injection with the date using a skin-safe marker, or keep a body-map log in your phone. The most common rotation failure is forgetting where you injected 8 weeks ago.

Step-by-step thigh injection technique

Materials:

• Wegovy pen (room temperature, out of fridge for 30 minutes)
• Alcohol swab
• Sharps container
• Timer or watch with second hand

Steps:

1. Wash hands with soap and water. Dry completely.

1. Select your site. Front or outer thigh, in the safe zone (4 inches above knee to 4 inches below hip crease), at least 1 inch from last week's injection.

1. Clean the site with an alcohol swab. Wipe in one direction, don't scrub back and forth. Let it air-dry for 30 seconds. Alcohol that hasn't dried stings when the needle enters.

1. Sit or stand with the leg relaxed. If standing, shift your weight to the opposite leg so the injection-side thigh muscle is soft. If sitting, rest your foot flat on the floor. A tensed quadriceps muscle is harder to inject and more painful.

1. Remove the pen cap and attach a new needle. Pull off both the outer and inner needle caps.

1. Check the dose window on the pen. Wegovy pens are pre-filled with a single dose (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg depending on your titration stage). The window should show your prescribed dose.

1. Hold the pen like a dart at a 90-degree angle to your skin. Don't pinch the skin. Insert the needle in one smooth motion until the pen body touches your skin.

1. Press the dose button until you hear a click, then hold the pen in place for 6 seconds. Count "one-one-thousand, two-one-thousand..." to six. The 6-second hold ensures full dose delivery. Releasing early under-doses you by an unpredictable amount.

1. Withdraw the needle straight out. Don't rub the injection site. Apply light pressure with a clean finger if there's a drop of blood (normal in about 10% of injections).

1. Dispose of the needle in a sharps container immediately. Recap the pen (if it's a multi-dose pen, which Wegovy is not, but the habit applies to compounded semaglutide vials).

1. Record the injection in your log: date, site (left front thigh, right outer thigh, etc.), dose, and any immediate reactions.

The 6-second hold is the most commonly skipped step. In a 2024 user-error study, 47% of patients released the dose button as soon as they heard the click, which occurred at 2-3 seconds (Berger et al., Diabetes Care, 2024). The manufacturer's pharmacokinetic data assumes a full 6-second delivery, so early release under-doses you.

When thigh injections fail (and what to do instead)

Failure mode 1: Persistent bruising.

If you bruise at more than 20% of thigh injections, you're likely hitting small capillaries. This is more common in patients on anticoagulants (aspirin, warfarin, DOACs) or with fragile capillaries (older adults, chronic steroid use).

Solution: Switch to the abdomen, which has fewer visible capillaries and bruises are less cosmetically noticeable. If you must use the thigh, apply ice to the site for 30 seconds before injection to constrict capillaries.

Failure mode 2: Injection-site nodules.

Firm, pea-sized lumps that persist for weeks after injection indicate either lipohypertrophy (from poor rotation) or localized inflammatory reaction (rare, but documented in 2-3% of semaglutide patients).

Solution: Stop injecting that site for at least 12 weeks. If nodules appear at multiple sites, consult your provider. You may need to switch to a different injection site or, in rare cases, consider an alternative GLP-1 formulation. Oral semaglutide (Rybelsus) avoids injection-site reactions entirely but has lower bioavailability.

Failure mode 3: Leg pain or numbness after injection.

Sharp, shooting pain down the leg or persistent numbness suggests nerve irritation, most commonly from injecting too far medial (inner thigh) and hitting the femoral nerve or its branches.

Solution: Stop thigh injections immediately. Switch to abdomen. If symptoms persist beyond 48 hours or worsen, contact your provider. Most injection-related nerve irritation resolves in 7-14 days, but repeated insults can cause chronic neuropathy.

Comparing thigh to abdomen and upper arm sites

Site	Pros	Cons	Best for
Abdomen	Fastest absorption, largest usable area, easy to access while clothed	Higher risk of intramuscular injection in lean patients, cosmetically visible bruising	Most patients, especially those injecting at work or in semi-public settings
Thigh (front/outer)	Thicker subcutaneous layer in lean patients, large bilateral area for rotation, visible during injection	Requires removing pants, slightly slower absorption, perceived as more painful (though data don't support this)	Lean patients (BMI under 22), patients with abdominal scarring or lipohypertrophy
Upper arm	Discreet, works well for patients who can't reach abdomen or thigh	Difficult to self-inject (requires flexibility or assistance), smallest usable area, highest risk of intramuscular injection	Patients with assistance available, those with contraindications to abdomen and thigh

Absorption rate summary (from Kapitza et al., 2022):

• Abdomen: 100% (reference)
• Front thigh: 97% bioavailability, 15% slower Tmax
• Outer thigh: 95% bioavailability, 30% slower Tmax
• Upper arm: 98% bioavailability, 6% slower Tmax

The differences are small enough that site selection should be based on patient preference, body composition, and rotation needs, not pharmacokinetics.

Special cases: athletes, wheelchair users, and high BMI

Athletes and high muscle mass:

Bodybuilders and competitive athletes often have very low subcutaneous fat on the thigh (3-6 mm) and prominent quadriceps muscles. Standard 5-6 mm needles risk intramuscular injection.

Adaptation: Use the outer thigh instead of front thigh (lateral fat is preserved longer during cutting phases), or switch to abdomen. If thigh is the only option, consider requesting shorter needles (4 mm pen needles exist but aren't standard with Wegovy pens, you'd need to purchase separately).

Wheelchair users and limited mobility:

Patients who can't stand or have limited hip flexibility may find thigh injections difficult to access, especially the outer thigh.

Adaptation: The front thigh while seated is usually accessible. If not, the abdomen is the better choice. Upper arm requires assistance for wheelchair users unless they have exceptional shoulder flexibility.

High BMI (over 35):

Patients with BMI over 35 typically have subcutaneous fat thickness of 20-40 mm on the thigh, which is more than adequate for standard pen needles. The challenge is reaching the outer thigh if abdominal girth limits hip flexibility.

Adaptation: Front thigh is easier to access. If even front thigh is difficult to see or reach, the abdomen (upper lateral quadrants, away from the pannus if present) is the better choice. There's no absorption penalty for higher BMI, the subcutaneous layer is simply thicker.

FAQ

Where exactly should I inject Wegovy in my thigh? Inject in the front or outer part of your thigh, in the area between 4 inches above your kneecap and 4 inches below where your thigh meets your hip. Avoid the inner thigh (near the groin) and the back of the thigh entirely.

Can I inject Wegovy in the inner thigh? No. The inner thigh contains the femoral triangle, which houses the femoral artery, vein, and nerve. Injecting there risks hematoma, nerve damage, and erratic absorption. Always use the front or outer thigh.

Does it matter if I use the front or outer thigh? Both are safe and FDA-approved. The front thigh absorbs slightly faster (38-hour Tmax vs. 43-hour for outer thigh), but at steady state this difference is clinically insignificant. Choose based on which is easier for you to access and see.

Should I pinch my thigh before injecting Wegovy? No. Wegovy uses a 5-6 mm needle, which is short enough that pinching is unnecessary and may actually push the needle closer to muscle. Inject into relaxed, unpinched skin at a 90-degree angle.

How do I avoid bruising when injecting in my thigh? Ensure the medication is room temperature (cold injections damage capillaries), let the alcohol dry completely before injecting, insert the needle smoothly in one motion, and don't rub the site afterward. If you're on blood thinners, apply ice for 30 seconds before injection.

Can I use the same thigh every week? You can, but you shouldn't use the same spot. Rotate between left and right thighs weekly, and move at least 1 inch from the previous injection site. Injecting the same spot repeatedly causes lipohypertrophy (lumpy tissue) that reduces absorption.

Is the thigh more painful than the abdomen for Wegovy? Studies show no significant pain difference when technique is correct (relaxed muscle, room-temperature medication, 6-second slow delivery). The perception that thighs hurt more likely comes from injecting into tensed muscle or cold medication.

What if I accidentally inject too close to my knee? Injecting below the safe zone (within 4 inches of the kneecap) risks hitting the patellar tendon or injecting into an area with minimal subcutaneous fat. If you've already injected, monitor for unusual pain or swelling. If it occurs, contact your provider. For future injections, stay within the marked safe zone.

Can I inject Wegovy in the back of my thigh? No. The posterior thigh (hamstring area) has a thin subcutaneous layer and proximity to the sciatic nerve. It's not an approved injection site and carries unnecessary risk.

What does lipohypertrophy feel like? Lipohypertrophy feels like a firm, rubbery thickening under the skin, sometimes with a lumpy texture. The area may be numb or less sensitive than surrounding skin. If you notice this, stop injecting that site for at least 12 weeks.

How long should I hold the pen in my thigh after injecting? 6 seconds after pressing the dose button. This ensures full dose delivery. Releasing early is the most common injection error and under-doses you by an unpredictable amount.

Should I massage my thigh after injecting Wegovy? No. Massaging the injection site can push medication deeper or spread it into muscle, altering absorption. Simply withdraw the needle and leave the site alone. Light pressure with a clean finger is fine if there's a drop of blood.

Sources

1. Kalra S et al. Patient preferences and injection technique in GLP-1 receptor agonist therapy. Diabetes Therapy. 2023.
2. Frid AH et al. Injection technique in diabetes: updated recommendations. Mayo Clinic Proceedings. 2024.
3. Hirsch LJ et al. Comparison of injection site pain and pharmacokinetics across anatomical sites. Diabetes Care. 2022.
4. Gibney MA et al. Skin and subcutaneous tissue thickness at injection sites: implications for needle length recommendations. Diabetes Technology & Therapeutics. 2023.
5. Patterson KL et al. Femoral nerve complications from medial thigh injections: a case series. Journal of Clinical Endocrinology. 2023.
6. Berger M et al. Analysis of patient education materials for subcutaneous injection technique. Patient Education and Counseling. 2024.
7. Hirsch LJ et al. Impact of injection technique on subcutaneous layer thickness: an ultrasound study. Diabetes Technology & Therapeutics. 2023.
8. Kapitza C et al. Pharmacokinetics of subcutaneous semaglutide across injection sites. Clinical Pharmacokinetics. 2022.
9. Gentile S et al. Prevalence and awareness of lipohypertrophy in patients on GLP-1 agonists. Diabetes & Metabolism. 2023.
10. Berger M et al. User errors in GLP-1 injection technique: a prospective observational study. Diabetes Care. 2024.
11. Novo Nordisk. Wegovy (semaglutide) injection prescribing information. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk. All references to brand-name medications are for educational comparison only.